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analysis was from public documents, related audit reports, literature review, ob-
servations from the meetings of the NHI Benefits Negotiation responsible for rec-
ommending new technologies for the NHIBS and interviews with the meeting
participators. RESULTS: The Taiwan process for updating the NHIBS lacks the ap-
peals and enforcement conditions, and only partially follows the relevance and
publicity conditions. Only the reasonableness and transparency steps of the trans-
disciplinary model are partially fulfilled, but the priority setting process does not
satisfy responsiveness and accountability. CONCLUSIONS: The fairness and legit-
imacy of the priority-setting decision mechanism have not been established. The
lack of personnel engaged in health technology assessment and the desire for early
adoption of new technologies are an obstacle to achieving these conditions. Com-
prehensive changes in the priority-setting process should be made in order to
increase its acceptability among the different stakeholders.
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OBJECTIVES: To review the numbers of Phase III/IV clinical trials conducted in the
four Asian countries with the highest health care spending (China, Japan, Korea
and India), and the share of trials sponsored by the 12 multinational companies
(MNCs) with the highest revenues and profits, over the past 10 years. METHODS:
Searches were performed on ClinicalTrials.gov to identify industry-sponsored
Phase III/IV studies added in 2002, 2006 and 2011. The proportion of trials con-
ducted in China, Japan, Korea and India, and the percentages of trials sponsored by
12 MNCs (Pfizer, Johnson & Johnson, Merck, Abbott Laboratories, Eli Lilly, Bristol-
Myers Squibb, Amgen, Gilead Sciences, Mylan, Allergan, Biogen Idec and Gen-
zyme), were analysed. RESULTS: The total proportion of industry-sponsored Phase
III/IV trials in China, Japan, Korea and India increased over the time period studied
(5%, 17% and 22% in 2002, 2006 and 2011, respectively). In 2002 and 2006, the top 12
MNCs sponsored approximately one third of the Phase III/IV trials in the four coun-
tries. This figure, however, dropped to about 20% in 2011. Eight Phase III/IV studies
in 2011 were co-funded by one western manufacturer and an Asian firm. Notably,
no Asian partners were identified in the collaborative Phase III/IV trials in 2002 or
2006. CONCLUSIONS: The period of 2002-2011 saw an increase in the total number
of Phase III/IV trials conducted in the four Asianmarkets. However, the dominance
of the top MNCs in these markets seemed to be weakened during this period. Our
results also suggest that establishing partnerships with local companies might be
a key strategy for entering these major health care markets.
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OBJECTIVES: To compare the measurement precision and related properties be-
tween a short and generic instrument, 5-level EuroQoL Group’s 5-dimension (EQ-
5D-5L) questionnaire, and a longer and disease-specific measure Functional As-
sessment of Cancer Therapy – Breast (FACT-B) questionnaire in assessing breast
cancer patients. METHODS: This is an observational study of 269 Singaporean
breast cancer patients. To compare discriminative ability cross-sectionally and
longitudinally, the effect sizes (in standard deviation) of the EQ-5D-5L and the
FACT-B in relation to various health indicators were estimated. Test-retest reliabil-
ity was examined using the intraclass correlation (ICC) for patients with no change
in self-assessed performance status or quality of life. For each non-inferiority as-
sessment, a 90% confidence interval of the difference (FACT-B minus EQ-5D-5L) in
effect size or ICC was estimated and compared with a pre-defined non-inferiority
margin of 0.2. RESULTS: In a cross-sectional setting, the differences in the effect
size favored EQ-5D-5L and the 90% confidence intervals totally fell within the zone
that indicated the non-inferiority of the EQ-5D-5L (e.g. oncologist-assessed perfor-
mance status: –0.26 to 0.04; patient-assessed performance status: –0.48 to –0.16;
current evidence of disease: –0.28 to 0.08). In a longitudinal setting, the FACT-B
showed larger effect sizes and ICCs than the EQ-5D-5L. The confidence intervals,
however, overlapped the non-inferiority margin, thus non-inferiority in these two
aspects could not be confirmed. CONCLUSIONS: The EQ-5D-5L was non-inferior to
the FACT-B in discriminating breast cancer patients with different health condi-
tions cross-sectionally. Its longitudinal measurement properties need further in-
vestigations. Depending on the specific research aims of studies, the EQ-5D-5Lmay
serve as a reasonable alternative or supplementary instrument to the FACT-B in
assessing breast cancer patients’ health outcomes.
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OBJECTIVES: The Kidney Disease and Quality Of Life questionnaire (KDQOL-36) is a
shorter version of the Kidney Disease and Quality of Life-Short Form (KDQOL-SF), a
widely used health outcomes instrument for patients with chronic kidney dis-
eases. The aim of this study was to validate the KDQOL-36 in haemodialysis pa-
tients in Singapore. METHODS: Secondary KDQOL-SF (version 1.3) data collected
from a cross-sectional survey of haemodialysis patients attending the National
Kidney Foundation (NKF) dialysis centres from December 2006 to January 2007 in
Singapore was used. The KDQOL-SF items used to construct the KDQOL-36 scales
were analyzed to assess their psychometric properties. Internal consistency reli-
ability was assessed using Cronbach’s alpha. Criterion validity of the physical com-
ponent summary (PCS-12) and mental component summary (MCS-12) was as-
sessed by examining their correlation with the PCS-36 andMCS-36 calculated from
the KDQOL-SF. Item-to-scale correlation was examined and exploratory factor
analysis was performed to test the scaling assumptions of the KDQOL-36.
RESULTS: Totally 394 patients (male: 55.8%; mean age [SD]: 52.4 [11.7] years) com-
pleted the survey in English. Cronbach’s  value of the KDQOL-36 scales ranged
from 0.70 to 0.91. Correlation between the PCS-12 and PCS-36 was 0.75 and corre-
lation between MCS-12 and MCS-36 was 0.80. Correlation of items with their hy-
pothesized scales was higher than their correlation with other scales for all
KDQOL-36 items. Principle component factor analysis indicated a three-factor
structure for the generic items (variance accounted for: 63.8%) and a four-factor
structure for the disease-specific items (variance accounted for: 62.6%). The dis-
ease-specific scales and the PCS-12/MCS-12 were weakly to moderately correlated
(range of correlation: 0.28 to 0.41).CONCLUSIONS:TheKDQOL-36 appears a reliable
and valid measure of quality of life for haemodialysis patients in Singapore. More
research needs to be conducted to assess the construct validity of the instrument
using clinical data.
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OBJECTIVES: This study demonstrates how net benefit regression was used for
estimating censor adjusted cost-effectiveness of combination anti-HCV regimens
in an observational database study. METHODS: The Integrated Health Care Infor-
mation Services (IHCIS) National Managed Care Benchmark Database during Jan-
uary 1, 1997 to June 30, 2007, was used to identify study subjects with newly-
diagnosed HCV infection. First was to identify the primary effectiveness on time to
end-stage liver disease (ESLD) free survival and total direct cost during the follow-
up. Study perspective was the managed care organization with 2007 value of dol-
lars. Censored effectiveness and total cost of HCV care were adjusted with inverse
probability of weighting for the likelihood of being censored based on baseline
patient characteristics. The incremental net monetary benefit (INB) of antiviral
therapy (vs. no treatment) was estimated in the ordinary least square linear regres-
sion with adjustments for potential confounding. The INBs were tested with
White’s correction for heteroskedasticity. RESULTS: Patients at the time of HCV
diagnosed related cirrhosis, 48 weeks of initial combination antiviral regimens
(peg-interferon alpha and ribavirin) was cost-effective when the willingness-to-
pay value is $40,000 (INB, 4828, 95%, -14688-24345) but longer duration therapy
was not. Initial therapy appeared no difference in ESLD prevention for patients
with cirrhosis free, although the incidence of ESLD was low between treated and
no-treated patients. Cirrhosis presented strong impacts on treatment initiation.
Despite for cirrhosis and age, comorbid conditions had differential influence on
efficiency which were failed to take into account in prior modeling approach.
CONCLUSIONS: The propensity score adjusted net monetary benefit can be a valid
measure of cost-effectiveness in the practice setting with heterogeneous treat-
ment effects. Although prior modeling studies suggested that threshold value to
being cost-effectivewas lower in patientswithout cirrhosis, the results seemed not
hold after adjustments for the likelihood of starting treatment and unmeasured
bias.
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OBJECTIVES: Conventionally, generic quality of life health states, defined within
multi-attribute utility instruments, have been valued using a standard gamble or
time trade-off. Preference elicitation tasks for both are complicated, limiting the
number of health states each respondent can value, and therefore that can be
valued overall. Additionally, the two techniques have been shown to introduce bias
into health state valuation due to issues of (for example) discounting of future
events or risk preference. The objective of this research is to test an alternative
method for eliciting preferences for generic health states, and to produce an algo-
rithm for use in Australian cost-utility analyses.METHODS:We designed a DCE to
obtain values for SF-6D health states, and implemented it in an Australia-repre-
sentative online panel (n1,017). A range of specifications were estimated using a
random-effects probit model. Utility weights were then derived such that full
health and death were valued at 1 and 0 respectively. RESULTS: The results reflect
the broadly monotonic design of the SF-6D, and combination of levels to remove
illogical orderings did not lead to a poorer model fit. The most important dimen-
sions in the SF-6D were identified as physical functioning, pain, mental health and
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